These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37291044)

  • 1. How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
    Lu JY; Chang YY; Lee TW; Wu MH; Chen ZW; Huang YT; Lai TS; Er LK; Lin YH; Wu VC; Cheng HM; Kao HL; Jia-Yin Hou C; Wu KD; Chen ST; Liu FH
    J Formos Med Assoc; 2024 Mar; 123 Suppl 2():S91-S97. PubMed ID: 37291044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between screening for primary aldosteronism with and without drug adjustment.
    Hua Y; He Q
    Blood Press; 2024 May; 33(1):2350981. PubMed ID: 38824645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test.
    Li J; Yan H; Li L; Lin X; Zhao Z; Zhou C; Zhang Q
    Endocrine; 2024 Jan; 83(1):188-195. PubMed ID: 37924464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroidomics-Based Screening for Primary Aldosteronism: Impact of antihypertensive Drugs.
    Constantinescu G; Gruber S; Fuld S; Peitzsch M; Schulze M; Remde H; Kürzinger L; Yang J; Yen T; Williams TA; Müller L; Reincke M; Lenders JWM; Beuschlein F; Pamporaki C; Eisenhofer GF
    Hypertension; 2024 Oct; 81(10):2060-2071. PubMed ID: 39082132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.
    Jaffe G; Gray Z; Krishnan G; Stedman M; Zheng Y; Han J; Chertow GM; Leppert JT; Bhalla V
    Hypertension; 2020 Mar; 75(3):650-659. PubMed ID: 32008436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].
    Chen SX; Du YL; Zhang J; Gong YC; Hu YR; Chu SL; He QB; Song YY; Zhu DL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):868-72. PubMed ID: 17217708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD.
    Sinha AD; Agarwal R
    Clin J Am Soc Nephrol; 2019 May; 14(5):757-764. PubMed ID: 30425103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and trends in the drug treatment of essential hypertension.
    van Zwieten PA
    J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future treatments in hypertension: Can we meet the unmet needs of patients?
    Kanbay M; Copur S; Tanriover C; Ucku D; Laffin L
    Eur J Intern Med; 2023 Sep; 115():18-28. PubMed ID: 37330317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the medical treatment of primary aldosteronism.
    Lim PO; Young WF; MacDonald TM
    J Hypertens; 2001 Mar; 19(3):353-61. PubMed ID: 11288803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A compendium of antihypertensive therapy.
    Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Sep; 13(9):636-8. PubMed ID: 21896141
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
    Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
    Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine arterial hypertension: therapeutic approach in clinical practice.
    Mazza A; Armigliato M; Zamboni S; Rempelou P; Rubello D; Pessina AC; Casiglia E
    Minerva Endocrinol; 2008 Dec; 33(4):297-312. PubMed ID: 18923367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.